Global Fund Secures Access to Breakthrough HIV Prevention Drug Lenacapavir for Low- and Middle-Income Countries
The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today announced it has signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV prevention, for low- and middle-income countries (LMICs). This marks the first time in history that an HIV prevention product will be introduced in LMICs at the same time as in high-income countries — a significant milestone for global health equity.
Photo courtesy of Annie Spratt.
Source: The Global Fund (link opens in a new window)
- Categories
- Health Care
